Compare RCMT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | ELDN |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | 4930 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 291.8M |
| IPO Year | 1997 | 2014 |
| Metric | RCMT | ELDN |
|---|---|---|
| Price | $42.02 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $45.00 | $9.00 |
| AVG Volume (30 Days) | 59.8K | ★ 782.3K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 30.67 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.47 | N/A |
| Revenue Next Year | $10.09 | N/A |
| P/E Ratio | $34.21 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $1.35 |
| 52 Week High | $43.09 | $4.60 |
| Indicator | RCMT | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 30.37 |
| Support Level | $38.84 | $1.96 |
| Resistance Level | $42.54 | $3.18 |
| Average True Range (ATR) | 1.04 | 0.15 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 58.23 | 3.33 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.